Currently, there are 600.23M common shares owned by the public and among those 508.86M shares have been available to trade.
The company’s stock has a 5-day price change of -0.42% and 4.63% over the past three months. MPW shares are trading 20.25% year to date (YTD), with the 12-month market performance up to 44.82% higher. It has a 12-month low price of $3.35 and touched a high of $6.55 over the same period. MPW has an average intraday trading volume of 13.12 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.82%, 12.74%, and 0.71% respectively.
Institutional ownership of Medical Properties Trust Inc (NYSE: MPW) shares accounts for 64.95% of the company’s 600.23M shares outstanding.
It has a market capitalization of $2.85B and a beta (3y monthly) value of 1.42. The earnings-per-share (ttm) stands at -$4.44. The company has a debt-to-equity ratio at 1.69. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.57% over the week and 5.44% over the month.
Analysts forecast that Medical Properties Trust Inc (MPW) will achieve an EPS of 0 for the current quarter, 0 for the next quarter and 0 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0 while analysts give the company a high EPS estimate of 0. Earnings per share for the fiscal year are expected to decrease by -240.79%, and 102.52% over the next financial year.
Looking at the support for the MPW, a number of firms have released research notes about the stock. Colliers Securities stated their Buy rating for the stock in a research note on September 13, 2024, with the firm’s price target at $6.50. Exane BNP Paribas coverage for the Medical Properties Trust Inc (MPW) stock in a research note released on July 02, 2024 offered a Neutral rating with a price target of $4. Deutsche Bank was of a view on April 17, 2024 that the stock is Hold, while Colliers Securities gave the stock Neutral rating on April 10, 2024, issuing a price target of $10- $4.25. Exane BNP Paribas on their part issued Outperform rating on March 01, 2024.
